The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Metabolic profile of antipsychotic-naive individuals with non-affective psychosis
Open accessAbstract
Background: Some studies suggest individuals with schizophrenia have an increased risk of diabetes prior to antipsychotic use. Small sample sizes and the potential for confounding by hypercortisolaemia have decreased confidence in those results. Aims: To examine diabetes-related factors in newly diagnosed, antipsychotic-naive people with non-affective psychosis. Method: Participants with psychosis (the psychosis group; n = 50) and matched controls (the control group; n = 50) were given a 2 h oral glucose tolerance test. Fasting concentrations were also determined for adiponectin, interleukin-6 and C-reactive protein. Results: Compared with the control group, the psychosis group had significant increases in 2 h glucose and interleukin-6 concentrations, and in the prevalence of abnormal glucose tolerance (16% of psychosis group v. 0% of control group). Adiponectin and C-reactive protein concentrations did not differ significantly between the two groups. These findings could not be attributed to differences in cortisol concentrations, smoking, gender, neighbourhood of residence, body mass index, aerobic conditioning, ethnicity, socioeconomic status or age. Conclusions: Individuals with non-affective psychosis appear to have an increased prevalence of abnormal glucose tolerance prior to antipsychotic treatment, as well as abnormalities in a related inflammatory molecule. These underlying problems may contribute to the metabolic side-effects of antipsychotic medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saha, S., Chant, D., & McGrath, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1123 · Cited by 2,065
Glucose tolerance in adults after prenatal exposure to famine
Ravelli, A., van der Meulen, J., Michels, R., Osmond, C., Barker, D., Hales, C., & Bleker, O. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07244-9 · Cited by 1,606
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
Mortality and causes of death in schizophrenia in Stockholm County, Sweden
Ösby, U., Correia, N., Brandt, L., Ekbom, A., & Sparén, P. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00191-7 · Cited by 679
Glucocorticoid hormones and early brain development in schizophrenia
Ph.D., J. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00396-7 · Cited by 199
Cited by
Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.013 · Cited by 1,742
Self-citationGoldsmith, D. R., Rapaport, M. H., & Miller, B. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.3 · Cited by 1,683
Mitchell, A. J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., & De Hert, M. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr148 · Cited by 1,082
Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review
Ochoa, S., Usall, J., Cobo, J., Labad, X., & Kulkarni, J. (2012) · Schizophrenia Research and Treatment · doi:10.1155/2012/916198 · Cited by 735
Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis
Upthegrove, R., Manzanares-Teson, N., & Barnes, N. M. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.03.005 · Cited by 501
Impaired Glucose Homeostasis in First-Episode Schizophrenia: A Systematic Review and Meta-analysis
Pillinger, T., Beck, K., Gobjila, C., Donocik, J. G., Jauhar, S., & Howes, O. D. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.3803 · Cited by 457
Metagenome-wide association of gut microbiome features for schizophrenia
Zhu, F., Ju, Y., Wang, W., Wang, Q., Guo, R., Ma, Q., Sun, Q., Fan, Y., Xie, Y., Yang, Z., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15457-9 · Cited by 409
Beumer, W., Gibney, S. M., Drexhage, R. C., Pont-Lezica, L., Doorduin, J., Klein, H. C., Steiner, J., Connor, T. J., Harkin, A., Versnel, M. A., et al. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0212100 · Cited by 347
Fernandes, B. S., Steiner, J., Bernstein, H.-G., Dodd, S., Pasco, J. A., Dean, O. M., Nardin, P., Gonçalves, C.-A., & Berk, M. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.87 · Cited by 348
C-Reactive Protein Levels in Schizophrenia: A Review and Meta-Analysis
Miller, B. J., Culpepper, N., & Rapaport, M. H. (2014) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.micu.020813 · Cited by 267
Potential metabolite markers of schizophrenia
Yang, J., Chen, T., Sun, L., Zhao, Z., Qi, X., Zhou, K., Cao, Y., Wang, X., Qiu, Y., Su, M., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2011.131 · Cited by 253
Serum and gene expression profile of cytokines in first-episode psychosis
Di Nicola, M., Cattaneo, A., Hepgul, N., Di Forti, M., Aitchison, K. J., Janiri, L., Murray, R. M., Dazzan, P., Pariante, C. M., & Mondelli, V. (2013) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2012.06.010 · Cited by 217
“…psychosis, reporting higher serum or plasma levels of IL-1b, IL-6, IL-12, INFc, TNF- a, TGF- b and soluble IL-2 receptor (Ganguli and Rabin, 1989; Kim et al., 2000, 2002, 2004, 2009; Theodoropoulou et al., 2001; Crespo-Facorro et al., 2008; Fernandez-Egea et al., 2009; Song et al., 2009).”
BackgroundGalletly, C. A., Foley, D. L., Waterreus, A., Watts, G. F., Castle, D. J., McGrath, J. J., Mackinnon, A., & Morgan, V. A. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412453089 · Cited by 203
Pillinger, T., Osimo, E. F., Brugger, S., Mondelli, V., McCutcheon, R. A., & Howes, O. D. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sby160 · Cited by 190
Zuccoli, G. S., Saia-Cereda, V. M., Nascimento, J. M., & Martins-de-Souza, D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00493 · Cited by 157
“In addition, there was a higher prevalence of hyperglycemia and impaired glucose tolerance in schizophrenia patients when compared to healthy controls (Ryan et al., 2003; Spelman et al., 2007; Fernandez-Egea et al., 2008, 2009).”
BackgroundMartins-de-Souza, D., Harris, L. W., Guest, P. C., & Bahn, S. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3459 · Cited by 134
“Over the last 10-year period, numerous studies demonstrated the occurrence of hyperglycemia, impaired glucose tolerance, and = or insulin resistance in first-onset, antipsychotic, naı¨ve SZ patients (23, 24, 29, 75, 79, 84, 85).”
Hepgul, N., Pariante, C. M., Dipasquale, S., DiForti, M., Taylor, H., Marques, T. R., Morgan, C., Dazzan, P., Murray, R. M., & Mondelli, V. (2012) · Psychological Medicine · doi:10.1017/s0033291711002947 · Cited by 112
“2008) and, more recently, in patients with first-episode psychosis (SpernerUnterweger et al. 1999 ; Crespo-Facorro et al. 2008 ; Fernandez-Egea et al. 2009 ; Mondelli et al. 2011).”
BackgroundFernandez-Egea, E., Bernardo, M., Heaphy, C. M., Griffith, J. K., Parellada, E., Esmatjes, E., Conget, I., Nguyen, L., George, V., Stoppler, H., et al. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn169 · Cited by 103
Self-citationLee, E. E., Hong, S., Martin, A. S., Eyler, L. T., & Jeste, D. V. (2017) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.09.009 · Cited by 94
Garcia-Rizo, C., Fernandez-Egea, E., Miller, B. J., Oliveira, C., Justicia, A., Griffith, J. K., Heaphy, C. M., Bernardo, M., & Kirkpatrick, B. (2013) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2012.11.009 · Cited by 84
Self-citationBlood cell count in antipsychotic-naive patients with non-affective psychosis
Garcia‐Rizo, C., Casanovas, M., Fernandez‐Egea, E., Oliveira, C., Meseguer, A., Cabrera, B., Mezquida, G., Bioque, M., Kirkpatrick, B., & Bernardo, M. (2019) · Early Intervention in Psychiatry · doi:10.1111/eip.12456 · Cited by 43
Self-citationFernandez-Egea, E., García-Rizo, C., Miller, B., Parellada, E., Justicia, A., Bernardo, M., & Kirkpatrick, B. (2011) · Psychosomatic Medicine · doi:10.1097/psy.0b013e318230343f · Cited by 43
“and 42 male control subjects who had participated in a metabolic study described elsewhere (8) and in whom testosterone was assayed.”
BackgroundResultSelf-citationde Almeida, V., Alexandrino, G. L., Aquino, A., Gomes, A. F., Murgu, M., Dobrowolny, H., Guest, P. C., Steiner, J., & Martins-de-Souza, D. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109945 · Cited by 39
Proteome effects of antipsychotic drugs: Learning from preclinical models
Carboni, L., & Domenici, E. (2016) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201500087 · Cited by 16
Metadata
- Authors
- Fernandez-Egea, E., Bernardo, M., Donner, T., Conget, I., Parellada, E., Justicia, A., Esmatjes, E., Garcia-Rizo, C., & Kirkpatrick, B.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2009-05
- Volume
- 194
- Issue
- 5
- Pages
- 434-438
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2151726163
- Cited by
- 242
- References
- 5
- FWCI
- 11.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.